News

The stock market has performed relatively well since the beginning of the year although, of course, there is no guarantee that it will maintain that momentum. Who knows what curve ball the future

When looking to invest in dividend stocks, chasing high yields isn't always an advisable strategy. Companies with juicy yields are only worth investing in provided they can support their payouts. We

What's better than a stock that has delivered huge gains? That's easy: A stock that has delivered huge gains and still has a lot of room to run.

We asked three Motley Fool contributors to look among

Relax, do what you enjoy, and rake in money. That probably sounds like a great life for most people. Making it a reality isn't easy, but it's possible.

The key is to generate passive income. You'll

Image source: The Motley Fool.

Medtronic (NYSE: MDT)Q4 2024 Earnings CallMay 23, 2024, 8:00 a.m. ET

Ryan Weispfenning

Continue reading

Source Fool.com

Medtronic (NYSE: MDT) stock slipped 2.8% through 10:15 a.m. ET this morning despite beating earnings forecasts in its fiscal Q4 2024 earnings report.

Heading into earnings, analysts had the medical

The Great Recession ended nearly 15 years ago. Buying stocks toward the end of an economic slowdown can lead to some oversize returns down the road since that usually means you're buying them at

When it comes to investing, I often look for companies that generate strong amounts of free cash flow (FCF), and companies that can grow their FCF. One company that has proven that over the years is

There are plenty of reasons to buy a leading biopharma business like AbbVie (NYSE: ABBV), and investors just got at least a few more. Thanks to a large acquisition that came out of left field, it

The past couple of years haven't been easy ones to be a Pfizer (NYSE: PFE) shareholder. The windfall profits its COVID-19 products produced in the early days of the pandemic evaporated much faster

Wall Street is feeling pretty good about AbbVie's (NYSE: ABBV) performance in 2024 so far.

Louise Chen from Cantor Fitzgerald recently initiated coverage on the stock with an overweight rating. Chen

Investors looking to pad their passive income streams with high-yield dividend stocks have three excellent choices. If you have an extra $100 to invest, you could set yourself up with dividends from

Eli Lilly (NYSE: LLY) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight

CRISPR Therapeutics (NASDAQ: CRSP) is a star in the gene-editing therapy niche. The company made tremendous progress over the past few years, culminating in its first regulatory approval -- for

The healthcare industry is full of opportunities for long-term investors to become part-owner in compelling businesses that are changing the future for patients across countless disease areas. You

Dividend stocks tend to struggle in high-interest-rate environments. The core reason is investors have an abundance of low-risk, high-yield income options when interest rates spike.

Conversely, fund

Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others.

Eli Lilly (NYSE: LLY) and Regeneron

Your long-term investment portfolio should have meaningful exposure to healthcare stocks. People will always seek treatments for disease, so demand for the sector won't go away any time soon

There are many dividend stocks on the market. Some will eventually cut or suspend their payouts due to company-specific, economic, or broader market issues. Those aren't the kind of dividend stocks

Many investors hold a stake in AbbVie (NYSE: ABBV) because it offers exposure to the healthcare sector. Industry-based diversification, however, isn't all the pharmaceutical outfit brings to the

Pfizer (NYSE: PFE) stock has struggled over the past year, losing around 28% of its value. Its dividend payout, meanwhile, has continued to rise again and again. This combination has pushed the

There are several textbook arguments against monopolies. According to one of them, companies that control a market can lower the quality of their products with impunity.

However, Vertex

The stock market has taken investors for a wild ride these last few years. When you're investing in stocks for many years, though, even multiple tough market cycles shouldn't deter you from your